- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
The Mainstream Patient: May 23
Author(s):
This week's edition of the Mainstream Patients features stories about the top 10 best acne-fighting ingredients and medications in 2022, Bill Nye talks not using oil on the scalp, and more.
In this week’s edition, Self interviews Samantha Tan, Race Car Driver, on eczema and InStyle claims to list the only dermatologist-approved at home anti-aging device. Cosmopolitan lists the best acne treatments and Glamour talks hair oil. Elle explains supplements and Allure talks topical steroid withdrawl.
Race Car Driver Samantha Tan on Eczema, Mental Health, and Why Asian Representation Matters
This Is the One Anti-Aging Device a Dermatologist Recommends Using at Home
10 Best Acne-Fighting Ingredients, Medications, and Treatments of 2022
Bill Nye Is Begging You to Not Use Oil on Your Scalp
The Supplements To Consider Taking At Every Life Stage
What It's Like to Live With Topical Steroid Withdrawal
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
